Cargando…

Trimethoprim-sulfamethoxazole prophylaxis during treatment of granulomatosis with polyangiitis with rituximab in the United States of America: a retrospective cohort study

BACKGROUND: Antibiotic prophylaxis is recommended during ANCA-associated vasculitis (AAV) induction. We aimed to describe the frequency, persistence, and factors associated with trimethoprim-sulfamethoxazole (TMP-SMX) use in an adult population sample with granulomatosis with polyangiitis (GPA) trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Mendel, Arielle, Behlouli, Hassan, de Moura, Cristiano Soares, Vinet, Évelyne, Curtis, Jeffrey R., Bernatsky, Sasha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386686/
https://www.ncbi.nlm.nih.gov/pubmed/37516897
http://dx.doi.org/10.1186/s13075-023-03114-7
_version_ 1785081728870645760
author Mendel, Arielle
Behlouli, Hassan
de Moura, Cristiano Soares
Vinet, Évelyne
Curtis, Jeffrey R.
Bernatsky, Sasha
author_facet Mendel, Arielle
Behlouli, Hassan
de Moura, Cristiano Soares
Vinet, Évelyne
Curtis, Jeffrey R.
Bernatsky, Sasha
author_sort Mendel, Arielle
collection PubMed
description BACKGROUND: Antibiotic prophylaxis is recommended during ANCA-associated vasculitis (AAV) induction. We aimed to describe the frequency, persistence, and factors associated with trimethoprim-sulfamethoxazole (TMP-SMX) use in an adult population sample with granulomatosis with polyangiitis (GPA) treated with rituximab (RTX). METHODS: We identified adults with GPA treated with RTX within the Merative™ Marketscan® Research Databases (2011–2020). TMP-SMX prophylaxis was defined as a [Formula: see text] 28-day prescription dispensed within a month of starting RTX. We estimated TMP-SMX persistence, allowing prescription refill gaps of 30 days. Multivariable logistic regression and Cox proportional hazards regression assessed the factors associated with baseline TMP-SMX use and persistence, respectively. Covariates included age, sex, calendar year, insurance type, immunosuppressant use, hospitalization, and co-morbidities. RESULTS: Among 1877 RTX-treated GPA patients, the mean age was 50.9, and 54% were female. A minority (n = 426, 23%) received TMP-SMX with a median persistence of 141 (IQR 83–248) days. In multivariable analyses, prophylaxis was associated with prednisone use in the month prior to RTX ([Formula: see text] 20 mg/day vs none, OR 3.96; 95% CI 3.0–5.2; 1–19 mg/day vs none, OR 2.63; 95% CI 1.8–3.8), and methotrexate use (OR 1.48, 95% CI 1.04–2.1), intensive care (OR 1.95; 95% CI 1.4–2.7), and non-intensive care hospitalization (OR 1.56; 95% CI 1.2–2.1) in the 6 months prior to RTX. Female sex (OR 0.63; 95% CI 0.5–0.8) was negatively associated with TMP-SMX use. CONCLUSIONS: TMP-SMX was dispensed to a minority of RTX-treated GPA patients, more often to those on glucocorticoids and with recent hospitalization. Further research is needed to determine the optimal use and duration of TMP-SMX prophylaxis following RTX in AAV. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13075-023-03114-7.
format Online
Article
Text
id pubmed-10386686
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-103866862023-07-30 Trimethoprim-sulfamethoxazole prophylaxis during treatment of granulomatosis with polyangiitis with rituximab in the United States of America: a retrospective cohort study Mendel, Arielle Behlouli, Hassan de Moura, Cristiano Soares Vinet, Évelyne Curtis, Jeffrey R. Bernatsky, Sasha Arthritis Res Ther Research BACKGROUND: Antibiotic prophylaxis is recommended during ANCA-associated vasculitis (AAV) induction. We aimed to describe the frequency, persistence, and factors associated with trimethoprim-sulfamethoxazole (TMP-SMX) use in an adult population sample with granulomatosis with polyangiitis (GPA) treated with rituximab (RTX). METHODS: We identified adults with GPA treated with RTX within the Merative™ Marketscan® Research Databases (2011–2020). TMP-SMX prophylaxis was defined as a [Formula: see text] 28-day prescription dispensed within a month of starting RTX. We estimated TMP-SMX persistence, allowing prescription refill gaps of 30 days. Multivariable logistic regression and Cox proportional hazards regression assessed the factors associated with baseline TMP-SMX use and persistence, respectively. Covariates included age, sex, calendar year, insurance type, immunosuppressant use, hospitalization, and co-morbidities. RESULTS: Among 1877 RTX-treated GPA patients, the mean age was 50.9, and 54% were female. A minority (n = 426, 23%) received TMP-SMX with a median persistence of 141 (IQR 83–248) days. In multivariable analyses, prophylaxis was associated with prednisone use in the month prior to RTX ([Formula: see text] 20 mg/day vs none, OR 3.96; 95% CI 3.0–5.2; 1–19 mg/day vs none, OR 2.63; 95% CI 1.8–3.8), and methotrexate use (OR 1.48, 95% CI 1.04–2.1), intensive care (OR 1.95; 95% CI 1.4–2.7), and non-intensive care hospitalization (OR 1.56; 95% CI 1.2–2.1) in the 6 months prior to RTX. Female sex (OR 0.63; 95% CI 0.5–0.8) was negatively associated with TMP-SMX use. CONCLUSIONS: TMP-SMX was dispensed to a minority of RTX-treated GPA patients, more often to those on glucocorticoids and with recent hospitalization. Further research is needed to determine the optimal use and duration of TMP-SMX prophylaxis following RTX in AAV. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13075-023-03114-7. BioMed Central 2023-07-29 2023 /pmc/articles/PMC10386686/ /pubmed/37516897 http://dx.doi.org/10.1186/s13075-023-03114-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Mendel, Arielle
Behlouli, Hassan
de Moura, Cristiano Soares
Vinet, Évelyne
Curtis, Jeffrey R.
Bernatsky, Sasha
Trimethoprim-sulfamethoxazole prophylaxis during treatment of granulomatosis with polyangiitis with rituximab in the United States of America: a retrospective cohort study
title Trimethoprim-sulfamethoxazole prophylaxis during treatment of granulomatosis with polyangiitis with rituximab in the United States of America: a retrospective cohort study
title_full Trimethoprim-sulfamethoxazole prophylaxis during treatment of granulomatosis with polyangiitis with rituximab in the United States of America: a retrospective cohort study
title_fullStr Trimethoprim-sulfamethoxazole prophylaxis during treatment of granulomatosis with polyangiitis with rituximab in the United States of America: a retrospective cohort study
title_full_unstemmed Trimethoprim-sulfamethoxazole prophylaxis during treatment of granulomatosis with polyangiitis with rituximab in the United States of America: a retrospective cohort study
title_short Trimethoprim-sulfamethoxazole prophylaxis during treatment of granulomatosis with polyangiitis with rituximab in the United States of America: a retrospective cohort study
title_sort trimethoprim-sulfamethoxazole prophylaxis during treatment of granulomatosis with polyangiitis with rituximab in the united states of america: a retrospective cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386686/
https://www.ncbi.nlm.nih.gov/pubmed/37516897
http://dx.doi.org/10.1186/s13075-023-03114-7
work_keys_str_mv AT mendelarielle trimethoprimsulfamethoxazoleprophylaxisduringtreatmentofgranulomatosiswithpolyangiitiswithrituximabintheunitedstatesofamericaaretrospectivecohortstudy
AT behloulihassan trimethoprimsulfamethoxazoleprophylaxisduringtreatmentofgranulomatosiswithpolyangiitiswithrituximabintheunitedstatesofamericaaretrospectivecohortstudy
AT demouracristianosoares trimethoprimsulfamethoxazoleprophylaxisduringtreatmentofgranulomatosiswithpolyangiitiswithrituximabintheunitedstatesofamericaaretrospectivecohortstudy
AT vinetevelyne trimethoprimsulfamethoxazoleprophylaxisduringtreatmentofgranulomatosiswithpolyangiitiswithrituximabintheunitedstatesofamericaaretrospectivecohortstudy
AT curtisjeffreyr trimethoprimsulfamethoxazoleprophylaxisduringtreatmentofgranulomatosiswithpolyangiitiswithrituximabintheunitedstatesofamericaaretrospectivecohortstudy
AT bernatskysasha trimethoprimsulfamethoxazoleprophylaxisduringtreatmentofgranulomatosiswithpolyangiitiswithrituximabintheunitedstatesofamericaaretrospectivecohortstudy